SLC5A2 and type 2 diabetes mellitus: This cohort study evaluates the prevalence, temporal trends, and thrombotic complications of sodium-glucose cotransporter 2 inhibitor (SGLT2i)–induced erythrocytosis among adult patients with type 2 diabetes.